Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-52

Hi Krano

With respect, - and understanding your concern - but you are misinterpreting the toxicity statement. What they are saying is that there is no toxicity caused by Her-vaxx (unlike Herceptin). Patients on both arms of the study were receiving the Chemo (with it's associated toxicity). Patients who received both the Chemo and Her-vaxx showed no added toxicity. ie. the only toxicity was coming from the Chemo - not from Her-vaxx.

The Hazard Ratio is not as good as in the initial interim data back in November but it is still as good as the market leading drug Herceptin, without any of Herceptin's toxicity/side effects, and with lower cost and easier administration. So this is still an excellent result and strongly indicative of commercial viability. Don't forget that these patients are/were all at advanced stages of disease.

As with others here, I am intrigued by the reference to an "Investigator Sponsored Study." An Investigator Sponsored Study means someone else is involved. A possible partnership candidate?

I expect a follow up announcement on that. Time will tell.

Cheers

Dave